This study will assess the systemic exposure and pharmacokinetic parameters of GSK2894512
following twice daily topical administration of 1% and 2% cream in adult subjects with AD,
and will provide information about the systemic safety as well as local safety and
tolerability following twice daily application to up to 35% body surface area (BSA) of
affected skin of subjects with AD. It will be an open-label, sequential study consisting of 2
cohorts. A cohort of 6 subjects (Cohort 1) will apply GSK2894512 (cream, 2%) to affected skin
on an area ranging from 15 to 35% of the total BSA for 20 days plus a final dose on Day 21.
Cohort 2 will consist of 6 subjects that will apply 1% cream. Cohort 2 will follow the same
procedures as Cohort 1.